2023
The Impact of COVID-19 on Families With Pediatric Muscular Dystrophy Patients
Zubair A, Scharer K, Lembeck P, Ionita C, Roy B. The Impact of COVID-19 on Families With Pediatric Muscular Dystrophy Patients. Cureus 2023, 15: e41138. PMID: 37519528, PMCID: PMC10386847, DOI: 10.7759/cureus.41138.Peer-Reviewed Original ResearchPediatric patientsCOVID-19 pandemicMuscular dystrophyCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicParents/caregiversMuscular dystrophy patientsChart reviewCaregiver burdenHome ordersPerson visitsLong-term effectsNeuromuscular conditionsProvider careNeuromuscular disordersPatientsPsychosocial impactDystrophy patientsSchool closuresNeuromuscular disabilitiesMajority of familiesHealthcare servicesSocial distancing measuresCOVID-19Daily activities
2022
Intravenous Immune Globulins vs Plasma Exchange Usage in Patients with Neuromuscular and Neuro-immunological Conditions (P4-13.007)
Rethana M, Zubair A, Ma A, McAlpine L, Abulaban A, Nowak R, Roy B. Intravenous Immune Globulins vs Plasma Exchange Usage in Patients with Neuromuscular and Neuro-immunological Conditions (P4-13.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2392.Peer-Reviewed Original Research
2021
Influenza vaccination in autoimmune neuromuscular diseases: A survey of current practices and perceptions
Roy B, Litchman T, Torabi T, Nowak RJ. Influenza vaccination in autoimmune neuromuscular diseases: A survey of current practices and perceptions. Muscle & Nerve 2021, 63: 918-923. PMID: 33711167, DOI: 10.1002/mus.27224.Peer-Reviewed Original ResearchConceptsChronic inflammatory demyelinating polyneuropathyGuillain-Barré syndromeMyasthenia gravisInfluenza vaccinationInfluenza vaccineInflammatory demyelinating polyneuropathyAutoimmune neuromuscular diseaseAutoimmune neuromuscular disorderHistory of exacerbationsProfessional society recommendationsDemyelinating polyneuropathyGBS patientsVaccine recommendationsSociety recommendationsNeurology practitionersInternet-based surveyPatientsNeuromuscular diseaseUnmet needNeuromuscular disordersNeurologistsPractice settingsVaccinationVaccineRecommendation practices
2020
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews In Oncology/Hematology 2020, 157: 103186. PMID: 33309571, DOI: 10.1016/j.critrevonc.2020.103186.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHemorrhagic eventsVEGFR-TKICancer patientsOdds ratioVascular endothelial growth factor tyrosine kinase inhibitorVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsKinase inhibitorsHigh-grade bleedingSide effect profileStandard chemotherapeutic regimenFirst-choice treatmentConfidence intervalsRandom-effects modelTypes of cancerVEGFR-TKIsChemotherapeutic regimenPrimary outcomeClinical trialsHigh riskPlaceboComparative riskPatientsImmunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic
Kovvuru S, Nalleballe K, Onteddu SR, Sharma R, Jasti M, Kapoor N, Veerapaneni K, Yadala S, Dandu V, Archer R, Nowak RJ, Roy B. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. Journal Of The Neurological Sciences 2020, 420: 117230. PMID: 33256952, PMCID: PMC7837234, DOI: 10.1016/j.jns.2020.117230.Peer-Reviewed Original ResearchConceptsAutoimmune neuromuscular disorderImmunosuppressive therapyMultiple sclerosisChronic autoimmune neuromuscular disorderNeuromuscular disordersCOVID-19Electronic medical record dataAutoimmune neurological disordersRisk of hospitalizationOverall infection riskMedical record dataRegistry-based dataCorona Virus Disease 2019Expert opinion guidelinesCOVID-19 databaseClinical research platformImmunosuppressed patientsImmunotherapy regimensAdditional physiciansDisease 2019Diseases-10International ClassificationPatientsNeurological disordersHospitalizationExploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry – The EXPLORE-MG registry
Anil R, Kumar A, Alaparthi S, Sharma A, Nye JL, Roy B, O'Connor KC, Nowak RJ. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry – The EXPLORE-MG registry. Journal Of The Neurological Sciences 2020, 414: 116830. PMID: 32388060, DOI: 10.1016/j.jns.2020.116830.Peer-Reviewed Original ResearchConceptsMyasthenia gravisMG patientsContemporary patient cohortKey clinical featuresMuscle-specific kinaseMG clinicClinical featuresGeneralized diseaseOutcomes RegistryPatient cohortPatient outcomesTreatment responsivenessTreatment outcomesTreatment strategiesRegistry dataEpidemiological dataInterim analysisData registryOcular diseasesPatientsCommon data elementsAcetylcholine receptorsRegistryPatient careDiseaseDifferential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study
Litchman T, Roy B, Kumar A, Sharma A, Njike V, Nowak RJ. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. Journal Of The Neurological Sciences 2020, 411: 116690. PMID: 32028072, DOI: 10.1016/j.jns.2020.116690.Peer-Reviewed Original ResearchConceptsMyasthenia gravisMGFA classRetrospective studyPositive myasthenia gravis patientsSingle-center retrospective studyManagement of MGAcetylcholine receptor autoantibodiesRefractory myasthenia gravisSymptom-free stateB-cell depletionMyasthenia gravis patientsClinical remissionClinical improvementDurable responsesMG patientsGravis patientsReceptor autoantibodiesMore hospitalizationsClinical symptomsExamination findingsCell depletionTreatment responsePatientsRituximabB cells
2019
Electrical impedance myography as a biomarker of inclusion body myositis: A cross-sectional study
Roy B, Rutkove SB, Nowak RJ. Electrical impedance myography as a biomarker of inclusion body myositis: A cross-sectional study. Clinical Neurophysiology 2019, 131: 368-371. PMID: 31865137, DOI: 10.1016/j.clinph.2019.10.030.Peer-Reviewed Original ResearchConceptsInclusion body myositisManual muscle testingIBM patientsElectrical impedance myographyHealthy controlsBody myositisClinical outcome measuresCross-sectional studyImpedance myographySimilar age groupLongitudinal validation studyPotential objective biomarkersBilateral deltoidHandgrip dynamometryWalk testMuscle testingTibialis anteriorObjective biomarkersMedial gastrocnemiusOutcome measuresPatientsAge groupsFinal analysisMyositisMyographyNeuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
Roy B, Das A, Ashish K, Bandyopadhyay D, Maiti A, Chakraborty S, Stone ME, Philpotts LL, Nowak RJ, Patwa HS. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis. Neurology 2019, 93: e143-e148. PMID: 31167931, DOI: 10.1212/wnl.0000000000007743.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyVEGFR-TKISensory neuropathyRelative riskVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsTyrosine kinase inhibitor useReceptor tyrosine kinase inhibitorsRisk of neuropathyStandard chemotherapeutic regimenVEGFr-TKI therapyVEGFR-TKI treatmentTyrosine kinase inhibitorsVEGFR-TKIsChemotherapeutic regimenInhibitor usePrimary outcomeClinical trialsNeuropathyHigh riskPatientsKinase inhibitorsCancerStrong associationIndividual treatment
2018
Comparison of treatment options for depression in heart failure: A network meta-analysis
Das A, Roy B, Schwarzer G, Silverman MG, Ziegler O, Bandyopadhyay D, Philpotts LL, Sinha S, Blumenthal JA, Das S. Comparison of treatment options for depression in heart failure: A network meta-analysis. Journal Of Psychiatric Research 2018, 108: 7-23. PMID: 30419488, DOI: 10.1016/j.jpsychires.2018.10.007.Peer-Reviewed Original ResearchConceptsHeart failure patientsStandardized mean differenceHF patientsFailure patientsClinical trialsDepressive symptomsConfidence intervalsRandom-effects modelPlacebo-controlled conditionsUsual standardWeb of ScienceUsual careHeart failurePrimary outcomeSuch patientsMeasures of depressionPoor outcomeTreatment optionsOvid MEDLINETherapeutic effectTherapeutic benefitElectronic searchPatientsMean differenceDifferent interventions